Pricing
  1. US-listed companies
  2. Regenicin, Inc.
  3. Financials
  4. Stockholders' equity

Regenicin, Inc.【RGIN】

Market cap
$15.35K
P/E ratio
SummaryFinancials
Period EndStockholders' equity (Million USD)YoY (%)
Sep 30, 2021-5+20.46%
Sep 30, 2020-4+15.01%
Sep 30, 2019-4+24.25%
Sep 30, 2018-3+22.88%
Sep 30, 2017-2+66.31%
Sep 30, 2016-1+91.14%
Sep 30, 2015-1-49.36%
Sep 30, 2014-2-63.36%
Sep 30, 2013-4+810.87%
Sep 30, 2012-0-128.09%
Sep 30, 20112

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)